Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ranbaxy Officially Becomes A Daiichi Subsidiary As Management Turns To Business Synergies

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Daiichi Sankyo has acquired 52.5 percent of Ranbaxy's equity share capital for $736 million. Ranbaxy announced that the committee of the board of directors of Ranbaxy approved Oct. 20 the allotment of equity shares and warrants on a preferential basis to Daiichi Sankyo. With this Ranbaxy has officially become a subsidiary of Daiichi Sankyo

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel